Immunic (NASDAQ:IMUX) Upgraded to “Hold” at StockNews.com

StockNews.com upgraded shares of Immunic (NASDAQ:IMUX) from a sell rating to a hold rating in a research note released on Friday morning.

Other equities analysts also recently issued research reports about the stock. Piper Sandler reissued an overweight rating and issued a $28.00 target price on shares of Immunic in a report on Tuesday, July 16th. Brookline Capital Management reissued a buy rating and issued a $10.00 target price on shares of Immunic in a report on Friday, April 5th.

Immunic Price Performance

Shares of NASDAQ:IMUX opened at $1.25 on Friday. Immunic has a 1-year low of $0.95 and a 1-year high of $2.01. The company has a market capitalization of $112.60 million, a P/E ratio of -0.68 and a beta of 1.76. The firm’s 50 day simple moving average is $1.25 and its two-hundred day simple moving average is $1.27.

Immunic (NASDAQ:IMUX) last released its earnings results on Wednesday, May 8th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.02. On average, sell-side analysts anticipate that Immunic will post -0.94 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immunic

Several large investors have recently bought and sold shares of IMUX. Virtu Financial LLC bought a new stake in Immunic in the first quarter worth $25,000. Summit Trail Advisors LLC bought a new position in Immunic during the first quarter valued at $25,000. Sierra Summit Advisors LLC bought a new position in Immunic during the fourth quarter valued at $487,000. Ikarian Capital LLC increased its position in Immunic by 258.3% during the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock valued at $2,128,000 after acquiring an additional 1,162,378 shares during the last quarter. Finally, Gratus Capital LLC increased its position in Immunic by 15.1% during the fourth quarter. Gratus Capital LLC now owns 1,941,454 shares of the company’s stock valued at $2,912,000 after acquiring an additional 254,999 shares during the last quarter. Institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.